Mount Sinai Receives $4.2 Million to Establish Proteogenomics Data Analysis Center

The National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research has awarded $4.2 million over five years to Mount Sinai researchers establishing a Proteogenomics Data Analysis Center (PGDAC) to advance cancer research and treatment. Proteogenomics, which studies the roles of proteins and genes within a cell or an organism, is a crucial area of ​​exploration to deepen our understanding of cancer.

The award supports the Centre’s work to identify potential biomarkers and drug targets for cancer, new insights into cancer biology, and bioinformatics tools to enable more advanced exploration and discovery from linked data sets. to cancer.

The Centre’s principal investigators, Pei Wang, PhD, Professor of Genetic and Genomic Sciences, and Avi Ma’ayan, PhD, Professor of Pharmacological Sciences and Director of the Mount Sinai Center for Bioinformatics, will contribute their expertise in statistics/biostatistics, machine learning, data integration, systems pharmacology and modeling of proteomic data to better understand the proteogenomic complexity of tumors.

The Centers of Excellence are part of NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) program, a national effort to advance and accelerate cancer research through the application of proteogenomics. Mount Sinai is one of 14 CPTAC centers nationwide.

The data generated and tools developed by the CPTAC centers will be made available to the public to help advance and accelerate cancer research.


Mount Sinai Health System

Comments are closed.